Blockade of the KRAS-FOSL1 axis elicits DNA damage repair deficiency exploitable with local and systemic genotoxic therapies

Read full text Summarise with VIRAT
Authors: Silvestre Vicent, Connor Welch, Gabriela Novoa, Carlos Vasquez-Valencia, Irati Macaya, Julio Jose Jimenez-Alonso, Alessia Subrizio, A. Fernandez Lagos, Sofia Llorente, Marta Jimenez, Rosario Prados‐Carvajal, Haritz Moreno
+19 more I. López, Nerea Bakartxo, Jonathan Rub, Andrea Crescencia Domingo Ratia, Paolo Battuello, Xabier Bujanda Cundin, Pablo Huertas, Teresa Macaruya, Luis G Paz-Ares, Giovanni Crisafulli, Alfonso Calvo, Elizabeth Guruceaga, Tuomas Tammela, Rafael Martínez‐Monge, Fernando Lecanda, Alberto Bardelli, Irene Ferrer, Tian V. Tian, Mariangela Russo
Cited by: 0
References: 47

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The clinical approval of direct KRAS inhibitors represents a milestone in precision oncology. Nonetheless, resistance heterogeneity limits durable clinical responses and impedes the nomination of a ‘‘one-size-fits-all’’ strategy for combination therapies. We circumvent this impasse by uncovering a core vulnerability elicited by KRAS blockade which transcends tissue origin, KRAS mutation, intrinsic KRASi sensitivity, and clinically relevant concurrent mutations. Specifically, we show that KRAS inhibition elicits a functional deficit in DNA damage repair by transcriptionally repressing homologous recombination. This BRCAness phenotype constitutes a conditional synthetic lethality to PARP inhibitors and radiotherapy, which synergize with single KRAS blockade and significantly delay the onset of secondary resistance. Integrative analyses identify the transcription factor FOSL1 as an upstream regulator of homologous recombination whose depletion sensitizes to PARP inhibition and radiotherapy. Collectively, we define a translational trajectory for the combination of KRAS inhibitors with clinically approved DNA-damaging agents as a therapeutic strategy treatment potentially expandable to most, if not all, mutant KRAS cancers.

Fields of Study & Subjects

PARP inhibition in cancer therapy Protein Kinase Regulation and GTPase Signaling DNA Repair Mechanisms

Publication details

Journal / source
Research Square
Publication date
31 March 2026
Language
EN
Document type
Preprint